Segmentation, Major Trends, and Competitive Overview of the Chronic Kidney Disease Market

The chronic kidney disease market is on the verge of significant expansion as healthcare advancements and growing patient awareness continue to drive demand. With increasing emphasis on early diagnosis and innovative treatments, this sector is set to experience noteworthy growth in the coming years. Let's explore the current market size, leading players, key trends, and segmentation details shaping the future of this healthcare niche.

Forecasted Market Size and Growth Outlook for the Chronic Kidney Disease Market
The chronic kidney disease market is projected to reach $95.43 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.3%. This anticipated rise is fueled by a combination of factors including focused healthcare policies, advancements in precision medicine, increasing obesity rates, the prevalence of chronic illnesses, and improved accessibility to healthcare services. Important trends expected to influence the market during this period include widespread early screening initiatives, the adoption of telemedicine and remote patient monitoring, programs designed to empower patients, community-based care models, and the integration of nutritional therapies.

Download a free sample of the chronic kidney disease market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11969&type=smp

Leading Players Steering the Chronic Kidney Disease Market
Several prominent companies dominate the chronic kidney disease market. These include Pfizer Inc, Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Mission Therapeutics Ltd., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, and ProKidney Corp.

AstraZeneca's Strategic Acquisition to Enhance Cardiorenal Portfolio
In a notable development during January 2023, AstraZeneca Pharmaceuticals LP acquired CinCor Pharma Inc. for $1.8 billion. This US-based biopharmaceutical company's acquisition brings CinCor's promising candidate, baxdrostat (CIN-107)-an aldosterone synthase inhibitor aimed at managing treatment-resistant hypertension-into AstraZeneca's cardiorenal pipeline. CinCor Pharma focuses on clinical-stage treatments for resistant hypertension and chronic kidney disease, enhancing AstraZeneca's position in these therapeutic areas.

View the full chronic kidney disease market report:
https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Innovation Trends Accelerating Market Growth in Chronic Kidney Disease
Product innovation stands out as a crucial driver for growth in the chronic kidney disease market. Companies continue to develop cutting-edge therapies to maintain competitive advantage. For example, in August 2022, Bayer introduced Kerendia (finerenone), a novel medication designed to slow chronic kidney disease progression in diabetic patients. This first-in-class non-steroidal, selective mineralocorticoid receptor antagonist functions differently from existing treatments by blocking mineralocorticoid receptor overactivation, which is linked to CKD advancement and cardiovascular complications.

Breaking Down the Chronic Kidney Disease Market Segmentation
This market is categorized across several key segments:
1) Diagnosis Methods: Blood Test, Urine Test, Imaging Test, Kidney Biopsy
2) Treatment Types: Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test, Other Treatments
3) Administration Routes: Oral, Intravenous, Subcutaneous
4) End-Users: Hospitals and Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers, Other End-Users

Further detailed subsegments include:
- Blood Test types such as Serum Creatinine Test, Glomerular Filtration Rate (GFR) Test, Blood Urea Nitrogen (BUN) Test, and Electrolyte Tests
- Urine Test categories like Urinalysis, 24-hour Urine Collection, Urine Protein Test, and Urine Albumin-To-Creatinine Ratio (ACR)
- Imaging Test methods including Ultrasound, CT Scan, MRI, and X-ray
- Kidney Biopsy procedures categorized into Percutaneous Kidney Biopsy, Open Kidney Biopsy, and Laparoscopic Kidney Biopsy

This detailed segmentation helps provide a comprehensive understanding of the market's diverse diagnostic and treatment options, highlighting the scope for specialized care in chronic kidney disease management.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.